GW Pharmaceuticals plc
https://www.gwpharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GW Pharmaceuticals plc
Acceleron To Be Next M&A Target With Rumored $11bn Deal
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
Raising The Stakes: Immunocore’s Next Play
Two years into her tenancy as CEO, Bahija Jallal is on the cusp of taking UK biotech Immunocore from a research and development organization to a company with a burgeoning pipeline and a marketed therapy. She talks to In Vivo about validating the platform, an IPO and creating a commercial footprint.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Jazz Gets Second Indication For Xywav As First Therapy For Idiopathic Hypersomnia
Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Greenwich Biosciences, Inc.
- Jazz Pharmaceuticals plc